Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2022 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across portfolio WORCESTER, Mass., Dec. 19, 2022 (GLOBE...
November 14, 2022 16:05 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
October 27, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom's Macroglobulinemia

MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred Hutch’s Dr. Mazyar Shadman WORCESTER, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) --...
October 06, 2022 08:30 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Enrollment continues in clinical trial of MB-106 under Mustang’s IND; next data disclosure anticipated 4Q 2022 Ongoing clinical trial of MB-106 at Fred Hutch continues to demonstrate high efficacy,...
September 08, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio to Participate in Upcoming September 2022 Investor Conferences

WORCESTER, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
August 11, 2022 16:05 ET | Source: Mustang Bio, Inc.

Mustang Bio Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

WORCESTER, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
July 27, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency

WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
June 22, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia

WORCESTER, Mass., June 22, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in...
June 13, 2022 08:00 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

94% overall response rate and 78% complete response rate in patients with FL, including complete response in a patient previously treated with CD19-targeted CAR T therapy 100% overall response rate...
May 19, 2022 08:45 ET | Source: Mustang Bio, Inc.

Mustang Bio Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

All 23 treated patients are alive at 2.6-year median follow-up without evidence of malignant transformation Data representing largest cohort of infants with XSCID treated with gene therapy presented...